Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients with Myocardial Infarction with Nonobstructive Coronary Artery Disease

Circulation

Volumn 135, Issue 16, 2017, Pages 1481-1489

  Lindahl, Bertil ^a   Baron, Tomasz ^a   Erlinge, David ^b   Hadziosmanovic, Nermin ^a   Nordenskjöld, Anna ^c   Gard, Anton ^a   Jernberg, Tomas ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Örebro University   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

adrenergic beta antagonists; coronary angiography; hydroxymethylglutaryl CoA reductase inhibitors; myocardial infarction; prognosis; renin angiotensin system; secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONOBSTRUCTIVE CORONARY ARTERY DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; CLINICAL PROTOCOL; MYOCARDIAL INFARCTION; SECONDARY PREVENTION;

AGED; CLINICAL PROTOCOLS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; SECONDARY PREVENTION;

EID: 85014056947     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.026336     Document Type: Article

References (31)

1. Beltrame JF. Assessing patients with myocardial infarction and nonobstructed coronary arteries (MINOCA). J Intern Med. 2013;273:182-185. doi: 10.1111/j.1365-2796.2012.02591.x.
2. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Ca-forio AL, De Caterina R, Zimarino M, Roffi M, Kjeldsen K, Atar D, Kaski JC, Sechtem U and Tornvall P. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2016;38:143-153.
3. von Korn H, Graefe V, Ohlow MA, Yu J, Huegl B, Wagner A, Gruene S, Lauer B. Acute coronary syndrome without significant stenosis on angiography: characteristics and prognosis. Tex Heart Inst J. 2008;35:406-412.
4. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015;131:861-870. doi: 10.1161/CIRCULATIONAHA.114.011201.
5. Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. Eur Heart J. 2015;36:475-481. doi: 10.1093/eurheartj/ehu469.
6. Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jepps-son A, Lagerqvist B, Lindahl B, Stenestrand U, Wallentin L. The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96:1617-1621. doi: 10.1136/hrt.2010.198804.
7. SWEDEHEART. http://www.swedeheart.se
8. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, Mc-Fadden E, De Feyter PJ, Specchia G, Ruzyllo W; Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809-1840.
9. Lee BK, Lessler J, Stuart EA. Weight trimming and propensity score weighting. PLoS One. 2011;6:e18174. doi: 10.1371/jour-nal.pone.0018174.
10. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lin-dahl B; TOTAL-AMI study group. Impact on long-term mortality of presence of obstructive coronary artery disease and classification of myocardial infarction. Am J Med. 2016;129:398-406. doi: 10.1016/j.amjmed.2015.11.035. Accessed December 28, 2016.
11. Feldman L, Steg PG, Amsallem M, Puymirat E, Sorbets E, Elbaz M, Ritz B, Hueber A, Cattan S, Piot C, Ferrieres J, Simon T, Danchin N. Medically managed patients with non-ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiog-raphy and extent of coronary artery disease [published online ahead of print January 12, 2016]. Eur Heart J Acute Cardiovasc Care. doi. org/10.1177/2048872615626354 http://journals.sagepub.com/ doi/abs/10.1177/2048872615626354?url-ver=Z39.88-2003&rfr- id=ori%3Arid%3Acrossref.org&rfr-dat=cr-pub%3Dpubmed&
12. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Black-well L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-2561. doi: 10.1016/S0140-6736(16)31357-5.
13. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56-62.
14. Calabrò P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol. 2005;20:541-546.
15. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators [see comments]. Lancet. 1993;342:821-828.
16. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Mag-gioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leim-berger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906. doi: 10.1056/NEJMoa032292.
17. Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Böhm M. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97:418-431. doi: 10.1007/s00392-008-0668-3.
18. Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG. Angio-tensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med. 2006;166:787-796. doi: 10.1001/archinte.166.7.787.
19. Grassi G, Seravalle G, Mancia G. Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. Eur J Clin Invest. 2015;45:1367-1375. doi: 10.1111/eci.12553.
20. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344-e426.
21. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol Ç, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. doi: 10.1093/eurheartj/ehv320.
22. Agewall S, Eurenius L, Hofman-Bang C, Malmqvist K, Frick M, Jernberg T, Tornvall P. Myocardial infarction with angiographically normal coronary arteries. Atherosclerosis. 2011;219:10-14. doi: 10.1016/j.atherosclerosis.2011.04.036.
23. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340-1349. doi: 10.1001/jama.2012.12559.
24. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Ja-guszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschöpe C, Schultheiss HP, Laney CA, Rajan L, Mi-chels G, Pfister R, Ukena C, Böhm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Va-sankari T, Airaksinen KE, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Ga-liuto L, Crea F, Dichtl W, Franz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Lüscher TF. Clinical features and outcomes of takotsubo (stress) cardio-myopathy. N Engl J Med. 2015;373:929-938. doi: 10.1056/ NEJMoa1406761.
25. Puymirat E, Riant E, Aissoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrières J, Juillière Y, Simon T, Danchin N. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;354:i4801.
26. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. doi: 10.1056/NEJ-Moa010746.
27. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327.
28. Bluhm G, Hammar N, Alfredsson L, Pershagen G. Could time trends in myocardial infarction incidence be due to diagnostic inconsistency? A study of the validity of hospital discharge diagnoses. J Intern Med. 1998;244:357-358.
29. Stegmayr B, Asplund K. Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. Neuroepidemiology. 1992;11:204-213.
30. Ingelsson E, Arnlöv J, Sundström J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7:787-791. doi: 10.1016/j.ejheart.2004.12.007.
31. Hambraeus K, Tydén P, Lindahl B. Time trends and gender differences in prevention guideline adherence and outcome after myo-cardial infarction: Data from the SWEDEHEART registry. Eur J Prev Cardiol. 2016;23:340-348. doi: 10.1177/2047487315585293.